NCT03662841

Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to study the safety and tumor response of ACE for large HCC.

Detailed description

Transarterial treatment has been playing an important role in the treatment algorithm for patients with multifocal or large intrahepatic hepatocellular carcinoma not eligible for surgical resection, transplantation, or local ablative therapy. Among the patient group with intermediate tumor stage, in which the tumor dimension exceeds 10cm, the treatment outcome of conventional chemoembolization (cTACE), chemoembolization using drug eluting beads (DEB-TACE) and radioembolization using yttrium 90 is generally unsatisfactory. Some would consider HCC of size \>10cm a relative contraindication for cTACE because of the poor treatment outcome. However, there is no better alternative treatment for local control of these tumors. Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin has been found to be highly effective for local control of HCC as compared to cTACE in a case-control study. It is hypothesized that ACE is safe and effective for local control of large HCC of size \>10cm.

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
PROCEDURE	Ablative chemoembolization (ACE)	Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin

Timeline

• Start date: 2018-07-13
• Primary completion: 2023-04-17
• Completion: 2023-04-28
• First posted: 2018-09-10
• Last updated: 2023-05-03

Locations

1 site across 1 country: Hong Kong